HALO Halozyme Therapeutics Inc.

15.17
-0.08  -1%
Previous Close 15.25
Open 15.13
Price To Book 9.14
Market Cap 2192937927
Shares 144,557,543
Volume 575,003
Short Ratio
Av. Daily Volume 881,769

SEC filingsSee all SEC filings

  1. 8-K - Current report 181233515
  2. 8-K - Current report 181201333
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163136
  4. 8-K - Current report 181163046
  5. 8-K - Current report 181061539

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Phase 1b/2 open label trial initiation announced July 13, 2017.
PEGPH20 and atezolizumab
Pancreatic cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Phase 1/2 enrollment closed due to lack of efficacy.
FOLFIRINOX and PEGPH20
Pancreatic and gastric cancers
Phase 1/2 data at ESMO 2018 noted 29% PR and 21% SD. No further clinical development planned on the Phase 2 portion of study
Eribulin In Combination With PEGPH20
High-Hyaluronan (HA) HER2-negative breast cancer
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 dosing initiated March 2016. Noted November 26, 2018 new primary endpoint of overall survival and interim PFS analysis will not occur. Target number of OS events for final analysis est Aug - Nov 2019.
PEGPH20 - HALO-301
Pancreatic cancer
Approved September 12, 2014.
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 2 topline data released 1Q 2014
HTI-501
Celluoite
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer

Latest News

  1. Hedge Funds Are Betting On Halozyme Therapeutics, Inc. (HALO)
  2. Halo Labs Announces Strategic Partnership in Lesotho Africa
  3. See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
  4. Halo Labs Announces Start of Production in California
  5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)
  6. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. – HALO
  7. What You Must Know About Halozyme Therapeutics Inc’s (NASDAQ:HALO) Financial Strength
  8. The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
  9. Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Loxo Oncology
  10. Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival
  11. Edited Transcript of HALO earnings conference call or presentation 6-Nov-18 9:30pm GMT
  12. Today's Research Reports on Trending Tickers: Loxo Oncology and Halozyme Therapeutics
  13. Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  14. Halo Labs Announces Dispensary Sales for the Month of October
  15. Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
  16. Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates

SEC Filings

  1. 8-K - Current report 181233515
  2. 8-K - Current report 181201333
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163136
  4. 8-K - Current report 181163046
  5. 8-K - Current report 181061539
  6. 8-K - Current report 181053820
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181042458
  8. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181024025
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998508
  10. 8-K - Current report 18998441